New drug challenges blockbuster cancer treatment in major lung cancer trial
NCT ID NCT07362459
Summary
This study aims to see if a new drug called SCTB14 works better than the standard drug pembrolizumab (Keytruda) for people with a specific type of advanced lung cancer. It will involve about 246 adults whose cancer has spread, has no specific genetic drivers, and has not been treated before. The main goal is to see if SCTB14 can keep the cancer from getting worse for a longer time than the current standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.